Clinical Report: Pharmacological Approaches and Their Relationship with Key Neonatal Outcomes in Preterm Infants with Patent Ductus Arteriosus
Overview
This study evaluates the association between pharmacologic treatment strategies for patent ductus arteriosus (PDA) and major neonatal outcomes in preterm infants.
Background
Patent ductus arteriosus (PDA) is prevalent in preterm infants and is linked to significant neonatal complications. Understanding the impact of pharmacologic treatments on outcomes like bronchopulmonary dysplasia (BPD) and mortality is crucial. Current management strategies vary, and the effectiveness of different pharmacologic agents remains a topic of investigation.
Data Highlights
Outcome
Result
Composite outcome (BPD and/or mortality)
39 infants (51.3%)
Gestational age (median)
28 weeks (IQR 26–30)
Mean birth weight
1,076 ± 343 g
Treatment groups
Ibuprofen only (n = 31), Paracetamol only (n = 27), Sequential therapy (n = 18)
Key Findings
The study included 76 preterm infants treated for clinically significant PDA.
The composite outcome of BPD and/or mortality occurred in 51.3% of infants.
Gestational age was identified as the strongest independent predictor of BPD and/or mortality.
Treatment strategy (ibuprofen, paracetamol, or sequential therapy) was not independently associated with outcomes.
Residual confounding and limited statistical power may affect the conclusions drawn from the study.
Clinical Implications
Gestational age is a critical factor influencing outcomes in preterm infants with PDA.
Conclusion
The study indicates that pharmacologic treatment strategies for PDA do not independently influence major neonatal outcomes.
